I-CHARLOTTE, NC, iUNITED STATES, ngoJanuwari 28, 2021EINPresswire.com/ - I-SonaCare yezoNyango, i-LLC, umphuhlisi ophambili kunye nomenzi wobuchwephesha obugxile kubuchwephesha be-ultrasound (HIFU), uyonwabile ukunika ingxelo ngokupapashwa kweFocal Therapy ngokuthelekiswa neRadost Prostatectomy ye-non-Metastatic Prostate Cancer: Isifundo soPhononongo oluhambelana noManqaku (1 ) ikhutshwe nje kwiNdalo. Kolu hlalutyo, unyango olujolisiweyo kunye ne-radical prostatectomy zathelekiswa zisebenzisa i-1-to-1 propensity score-matched for year year, age, PSA, Gleason, T-Stage, ubude bomhlaza kunye nokusetyenziswa kwehomoni ye-neoadjuvant. Kwi-3, 5 kunye ne-8 iminyaka yokusilela kokuSinda kwaSimahla (FFS) ye-radical prostatectomy yayiyi-86%, i-82% kunye ne-79% xa kuthelekiswa ne-91%, i-86% kunye ne-83% ye-FFS yonyango olujolise ngexesha elinye. Kwakhona, kwinqaku leqondo lesibini unyango lwalumalunga ne-16% ye-radical prostatectomy kwaye malunga ne-17% kunyango olujolise kuyo.
U-Karen Cornett, usekela-Mongameli we-Clinical Operations, ye-SonaCare Medical, uthe, "Olu hlobo lokufunda luthelekisa utyando olukhulu kuthelekiswa nonyango olujolise kuyo, uninzi lwanyangwa nge-Sonablate HIFU, lubalulekile ngenxa yendlela ethelekise ngayo zombini iindlela zonyango. Olu thelekiso lubonisa ngokucacileyo izibonelelo zonyango oluncinci olungenasifo, olunyanga ngaphandle, olugxile kunyango olukhulu. Into yokuba izigulana ze-HIFU zikumaziko onyango kuphela iiyure ezimbalwa kwaye zifuna ubukho nje obuncinci kubasebenzi kwigumbi lokusebenza ziyenza ukuba ibengcono ngoku njengoko siphakathi kubhubhane we-COVID. ”
Isikhokelo sophando, uNjingalwazi Hashim Ahmed, enye yeengcali zomhlaza wamadlala endlala, uthe, “Siyazi ukuba malunga nomguli omnye kwabathathu otyandwe kakhulu ngenxa yomhlaza wedlala lobudoda uyazisola ngesigqibo sabo emva koko. Rhoqo oku kungenxa yokuba ungaziswanga ngokupheleleyo ngezinto ezinokhetho oluneziphumo ebezingalindelekanga ezimbalwa. Isifundo sethu sibonisile ukuba unyango olujolise ngqo kuthwala ukunciphisa okuphindwe kalishumi kukuvuza komchamo kunye neengxaki zesini. Ngokubalulekileyo, okokuqala sibonisa ukuba inolawulo lomhlaza olufanayo kwiminyaka emi-1 ukuya kwezi-3 emva konyango kwi-radical prostatectomy. ” Uye wongeza, "Ngelixa unyango olujolayo alulungelanga zonke izigulana, kukho amawaka ngonyaka afanelekileyo kwaye kufanelekile ukuba babe nolwazi ngalo."
(1) Shah, T., Reddy, D., et al. Ukutya Unyango lwe-Focal xa kuthelekiswa ne-radical prostatectomy yomhlaza we-Prostate cancer: isifundo esilinganayo sokulinganisa. Indalo. 2021. https://doi.org/10.1038/s41391-020-00315-y
Ukusukela kwi-Sonablate® ifumene ukucocwa kwe-FDA ngo-Okthobha 9, 2015, amawaka ezigulana abe nenkqubo ye-Sonablate HIFU yeprostate kwiindawo ezingama-60 + e-US, kubandakanya namaziko emfundo ephezulu eCalifornia, Indiana, Oklahoma, Maryland, New York, Arizona naseTexas . Ngaphezulu kwamagqirha angama-70 ase-US ngoku abonelela nge-HIFU yeprostate tissue ablation kwizigulana zabo njengenye indlela encinci yokungena kutyando okanye kwimitha.
Sonablate® ine-501 (K) yokususwa e-US kwaye ibonakalisiwe ekuguqulweni kokuqina okuphezulu kugxile kwi-ultrasound (HIFU) ablation yeprostate tissue. Isilumkiso: Umthetho waseburhulumenteni (i-USA) uthintela esi sixhobo ukuba sithengiswe ngugqirha okanye ngokomyalelo kagqirha.
Malunga ne-SONACARE MEDICAL, LLC
I-SonaCare yezoNyango iyinkokeli yehlabathi kubuchwephesha obuncinci obungena gwenxa kubuchwephesha be-ultrasound. I-SonaCare Medical izinikele ekuphuhliseni itekhnoloji enxulumene ne-ultrasound exhasa iinkqubo ezichanekileyo kunye neendlela ezintsha zonyango lweemeko zonyango. I-SonaCare Medical, kunye ne-subsidiary Focus Surgery, Inc., iyila kwaye yenze izixhobo zonyango, kubandakanya oku kulandelayo:®, ene-501 (K) imvume e-US; Sonablate®500, ene-CE Marking kwaye ifumene ugunyaziso lolawulo kumazwe angaphezu kwama-50 ngaphandle kwe-US, Sonatherm® Inkqubo ye-laparoscopic HIFU yoqhaqho, ene-510 (K) imvume e-US, ine-CE Marking kwaye ifumene ugunyaziso lolawulo kumazwe angaphezu kwama-30 ngaphandle kwe-US
Ngolwazi olongezelelweyo, ndwendwela www.SonaCareMedical.com
INGXELO EJONGE PHAMBILI
Iingxelo zeNkampani ezijonge phambili zisekwe kulindelo lwangoku kunye nentelekelelo malunga neshishini leNkampani kunye nokusebenza, uqoqosho kunye nezinye iimeko zexesha elizayo kunye noqikelelo lweziganeko zexesha elizayo, iimeko kunye neziphumo. Njengalo naluphi na uqikelelo okanye uqikelelo, iingxelo ezijonge phambili ngokwendalo zisesichengeni sokungaqiniseki kunye notshintsho kwiimeko. Ezona ziphumo zeNkampani zisenokwahluka ngokwezinto ezibonakalayo kwezo zichaziweyo okanye zichazwe kwiingxelo zayo ezijonge phambili. Nasiphi na isitatimenti esijonge phambili esenziwe yiNkampani sithetha kuphela ukusukela ngomhla esenziwa ngawo. Inkampani ayinyanzelekanga ukuba, kwaye iyazikhanyela naziphi na izibophelelo, ukuhlaziya okanye ukuguqula iingxelo ezijonge phambili, nokuba kungenxa yolwazi olutsha, iziganeko ezilandelayo okanye ezinye izinto.
UKaren Cornett
I-SonaCare yezoNyango
+ 1 704-805-1885
imeyile apha apha
INTO ONOKUYITHATHA KWELI NQAKU:
- The fact that HIFU patients are only in the medical facility for a few hours and require only a minimal presence of personnel in the operating room make it ideal especially now as we are in the midst of the COVID pandemic.
- At 3, 5 and 8 years Failure Free Survival (FFS) for radical prostatectomy was 86%, 82% and 79% compared to 91%, 86% and 83% FFS for focal therapy at the same time intervals.
- Since Sonablate® received FDA clearance on October 9, 2015, many thousands of patients have had a Sonablate HIFU prostate procedure across the 60+ locations in the U.
